INCY

Incyte

Halal Rating :
Comfortable
Last Price $69.07 Last updated:
Market Cap $12.69b
7D Change 0.76%
1 Year Change 11.96%
Company Overview Use of Interest Company Impact Justification for our Halal Rating Recent News

Company Overview

Industries
  • Services
  • Business Services
  • Services – Research
  • Development
  • Testing Labs
Exchange NASDAQ
Next Earnings Date Oct. 29, 2024

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company's primary focus is on oncology, inflammation, and autoimmune diseases. Their main product portfolio includes JAKAFI® (ruxolitinib), used for treating various blood disorders and PEMAZYRE® for treating cholangiocarcinoma.

Use of Interest

Reporting Date Total Revenue Total Operating Expense Interest Income Interest Expense Interest Income Ratio Interest Expense Ratio
Sept. 30, 2024 $1.14b $992.56m - $774000.0 0.00% 0.08%
June 30, 2024 $1.04b $1.52b - $657000.0 0.00% 0.04%
March 31, 2024 $880.89m $789.42m - $430000.0 0.00% 0.05%

Company Impact

Help us evaluate Incyte's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.

Contribute

Recent News & Updates